Rinicold Bronho (Rinicold Broncho)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbspsyrup
Composition:

for 10 ml of syrup:

Ambroxol hydrochloride 15.00 mg

Chlorphenamine maleate 2.0 mg

Phenylephrine hydrochloride 5.0 mg

Guaifenesin 100.0 mg

Excipients: sucrose 4000.00 mg, methyl parahydroxybenzoate 18.00 mg, propyl parahydroxybenzoate 2.00 mg, disodium edetate 2.00 mg, sorbitol 70% solution 1000.00 mg, glycerol (glycerol) 500.00 mg, menthol 1.00 mg, lemon acid 2.00 mg, sodium citrate 5.00 mg, melon flavor 0.03 ml, dye sunset yellow [E110] 0.66 mg, purified water q.s. up to 10 ml.

Description:

A thick solution from light orange to orange with a characteristic odor.

Pharmacotherapeutic group:remedy for the elimination of symptoms of acute respiratory disease and "colds".
ATX: & nbsp
  • Other combined drugs used for catarrhal diseases
    • Pharmacodynamics:

    Rinikold Broncho-syrup - a combined preparation, included in its composition guaifenesin and ambroxol reduce the viscosity of the bronchial secretion and facilitate expectoration. Chlorphenamine maleate has an anti-allergic effect: it eliminates tearing, itching in the eyes and nose. Phenylephrine hydrochloride has a vasoconstrictive effect, reduces swelling and hyperemia of the mucous membranes of the upper respiratory tract and accessory sinuses.

    Indications:

    Symptomatic treatment of "catarrhal" diseases, influenza and acute respiratory viral infections, accompanied by a cough with hard-to-remove viscous sputum.

    Contraindications:

    Hypersensitivity to any component of the drug, the simultaneous administration of other drugs containing substances included in Rinikold Broncho, the simultaneous administration of tricyclic antidepressants, monoamine oxidase inhibitors, beta-blockers, convulsions of any etiology, pronounced coronary artery atherosclerosis, arterial hypertension, diabetes, thyrotoxicosis, pheochromocytoma, zakratougolnaya glaucoma, peptic ulcer of the stomach and duodenum, prostate adenoma, enzyme deficiency glucose ozo-6-phosphate dehydrogenase, sucrose / isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption, pregnancy, lactation period, children's age (up to 6 years).

    Carefully:

    renal and / or hepatic insufficiency, children under 12 years of age

    Dosing and Administration:

    Shake before use!

    Recommended dose for adults and children over 12 years of age:

    20 ml (4 teaspoons) 3 times a day

    Recommended dose for children 6 - 12 years:

    10 ml (2 teaspoons) 2 - 3 times a day

    The drug should be evenly distributed throughout the day.

    Side effects:

    Possible elevation of arterial pressure tachycardia, headache, the appearance of drowsiness, dizziness, dry mucous membranes, impaired appetite, difficulty urinating, allergic reactions in the form of rashes and itching, hives, swelling Quincke; nausea, vomiting, constipation, diarrhea, epigastric pain, increased excitability, disturbed sleep, mydriasis, paralysis, accommodation, increased intraocular pressure, pheochromocytoma.

    Children may have arousal, anxiety and irritability. In the elderly, patients are also confused or irritable.

    Overdose:

    Increased severity of side effects. Treatment: gastric lavage, reception of activated carbon, laxatives (vaseline oil, salt laxatives); symptomatic therapy. In case of severe disorders, it is necessary to consult a doctor.

    Interaction:

    The drug enhances the effect of sedatives, ethanol. Joint use with antidepressants, phenothiazine derivatives (chlorpromazine, trifluoperazine, levomepromazine), antiparkinsonian and antipsychotic agents increases the risk of developing urinary retention,dry mouth, constipation, with glucocorticosteroids (prednisolone, dexamethasone, triamcinolone) increases the risk of developing glaucoma. Chlorphenamine when used concurrently with monoamine oxidase (nialamide) inhibitors, furazolidone can lead to hypertensive crisis, excitation, hyperpyrexia. Application together with tricyclic antidepressants strengthens their sympathomimetic effect, with halothane increases the risk of developing ventricular arrhythmia, with guanethidine reduces its hypotensive effect, which, in turn, enhances the alpha-adrenostimulating activity of phenylephrine. The simultaneous use of ambroxol and guaifenesin with antitussive drugs leads to difficulty in sputum discharge.

    Special instructions:

    It is not recommended to take the drug for more than 7 days without prescribing a doctor.

    It is possible to stain the urine pink.

    The drug should be used with caution in patients with a weakened cough reflex or disturbed mucociliary transport because of the possibility of sputum congestion.

    It is recommended to take a sufficient amount of liquid during treatment. Guaifenesin the preparation included in the preparation may give false positive results in determining 5-hydroxyindoleacetic and vinylylmandelic acids in the urine due to the effect of guaifenesin metabolites on color (gwayfenesin should be discontinued 48 hours before urine collection for this test).

    Effect on the ability to drive transp. cf. and fur:

    When taking the drug, you should refrain from driving and practicing potentially dangerous activities that require increased concentration and speed of psychomotor reactions.

    Form release / dosage:

    Cough syrup.


    Packaging:Primary: 100 ml each in glass bottles of dark glass, sealed with a screwed metal cover and controlled by the first opening. Secondary: one bottle per cardboard pack together with instructions for use
    Storage conditions:

    Store at a temperature not exceeding 25 ° C. Do not freeze.

    Keep out of the reach of children.


    Shelf life:
    3 years.
    Do not use after the date shown on the package.
    Terms of leave from pharmacies:Without recipe
    Registration number:LS-001244
    Date of registration:21.07.2011 / 04.10.2013
    The owner of the registration certificate:Shraya Life Senses Pvt. Ltd.Shraya Life Senses Pvt. Ltd. India
    Manufacturer: & nbsp
    Information update date: & nbsp02.02.2016
    Illustrated instructions
      Instructions
      Up